PA-SALADAX-BIOMEDICAL
23.9.2021 16:07:07 CEST | Business Wire | Press release
Salvatore J. Salamone, Ph.D. received the prestigious Dr. C.E. Pippenger Award at the 2021 International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting in Rome, Italy. This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that patients receive a personalized dose of drugs to achieve an optimum therapeutic result. Unfortunately, many medications, such as anticancer, antibiotics, and antifungal treatments, have severe toxicities when overdosed and are ineffective when underdosed. TDM seeks to ensure that the patient receives enough drug to treat the condition but not too much to cause toxicities and potentially death.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005035/en/
Dr. Salamone received this award for his contributions to TDM in oncology. He began his work in TDM of anticancer drugs after personally witnessing the adverse reactions caused by toxicity during chemotherapy treatment of family members. He made it his goal that no patient should ever be given anticancer drugs without TDM to ensure proper dosing. He has advocated establishing clinical guidelines for TDM and pharmacology in oncology for over 15 years.
Dr. Salamone accepted this award as a great honor and paid tribute to the influence Dr. Pippenger had on the field of TDM and on him personally. With over 30 years of experience developing diagnostics, Dr. Salamone is recognized globally in the field of drug monitoring and has published extensively in this area. In his acceptance speech, Dr. Salamone spoke about the significant role that TDM plays in personalized medicine.
Dr. Salamone went on to describe that the “unfortunate reality in oncology is that many, if not the majority of, patients are not receiving the correct dose of chemotherapy and we need to act.“ Dr Salamone continued, “Patients are needlessly suffering adverse effects because the dose is too high while others aren't receiving enough drug to treat the cancer effectively. Using the standard body surface area (BSA) dosing method developed in 1916 to administer chemotherapy is now obsolete. Welcome to the 21st century." He described the lack of knowledge of and resistance to TDM by the oncology community. “I urge all IATDMCT members to become more active in engaging the oncology community,” stated Dr Salamone. “Receiving this award inspires me to continue pursuing my goal of making TDM the standard of care in oncology.”
“We will not fully achieve the promise of personalized medicine until every patient receives the correct amount of drug for their body,” said Dr. Salamone. “As the first individual from industry to receive this prestigious award, I am deeply honored and touched that my life’s work has been recognized by such an esteemed organization.”
ABOUT SALADAX BIOMEDICAL, INC.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians monitor and optimize patient care, visit Saladax.com
For more information, visit Saladax.com or MyCareTests.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005035/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paymentology Raises $175 Million co-led by Apis Partners and Aspirity Partners to Support Next Phase of Growth12.5.2026 09:01:00 CEST | Press release
Paymentology, the leading global issuer-processor, today announced a $175 million investment co-led by Apis Partners (”Apis”), a private equity firm specialising in financial infrastructure and services, and Aspirity Partners (“Aspirity”), a pan-European Private Equity firm focused on Financial Technology & Services and Enterprise Technology & Connectivity Services. The investment will support Paymentology’s continued global expansion, product development and strengthening of its team, as the company builds on strong demand for modern issuer processing on a global scale. The transaction brings together two investors with deep experience in the payments industry and a shared focus on advancing payments infrastructure, united by the view that issuer processing represents one of the most significant opportunities in the sector. For Apis, the investment, made by Apis Growth Fund III1, marks the firm’s 16th payments investment. Both Apis and Aspirity will draw on their deep sector and globa
IQM Launches HPC Integration Service to Accelerate Hybrid Quantum-HPC Adoption12.5.2026 09:00:00 CEST | Press release
IQM Radiance systems now operate as computational nodes inside HPC environments. The hybrid workflows are scheduled and managed alongside CPUs and GPUs by the same workload manager already operational in the world’s top supercomputing centers. The new HPC Integration Service reflects the company’s production quantum model – end-users own the hardware, run it on their infrastructure, and operate it under their control. IQM Quantum Computers today launched HPC Integration Service, a turnkey solution that enables its IQM Radiance quantum computers to operate as a slurm node inside high-performance computing (HPC) environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512187465/en/ IQM Radiance quantum computer (right) co-located with classical HPC infrastructure (left) in a data center environment. Using this widely adopted HPC workflow, IQM aims at accelerating adoption of hybrid quantum-classical computing across ente
Visa Flexible Credential Brings More Flexible Ways to Pay to Zilch Cardholders in the UK12.5.2026 09:00:00 CEST | Press release
Visa, Zilch and Thredd collaborate to help issuers deliver a simpler, more flexible card experience for users. Visa, a world leader in digital payments, Zilch and Thredd today announced the introduction of Visa Flexible Credential (VFC) on Zilch cards in the UK, enabling more flexible ways to pay through a single, familiar card experience. Demand for flexible payment experiences continues to grow. Many people no longer think in fixed terms such as debit or credit, instead wanting the ability to choose what works best for a specific purchase in the moment. In the UK, 87% of people surveyed say flexible payment options support their financial or lifestyle goals1. Visa Flexible Credential is designed to support this shift, helping issuers offer more choice through one familiar card that already works at more than 150 million merchant locations worldwide. The new capability allows different payment options to sit behind one card or digital credential, giving cardholders greater choice and
AMP IT Announces New Funding Round to Scale Its Private EV Charging as a Service in Switzerland and Beyond12.5.2026 08:43:00 CEST | Press release
AMP IT, a Geneva-based energy and mobility company, today announced the successful completion of a new funding round to accelerate the deployment of its private EV charging and energy management platform across Switzerland and international markets. Founded in 2021, AMP IT develops, finances, installs, and operates smart EV charging infrastructure for residential buildings, commercial real estate, and corporate fleets. Through its charging-as-a-service model, the company combines infrastructure with its proprietary software, AMP IT Hub, delivering a fully integrated energy solution. The latest funding round, supported notably by the Swiss Technology Fund, brings AMP IT’s total funding to €7 million since inception. The capital will support operational scaling, further development of its software platform, and expansion into selected European markets. “Users are increasingly looking for solutions that are simple, efficient, and affordable which is exactly what we provide,” said Florian
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden12.5.2026 08:30:00 CEST | Press release
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering –− DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and only TTR silencer approved for ATTR-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom